Allarity issued a statement encouraging its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26. The Board has put a proposal before stockholders for a reverse stock split. Allarity has requested approval of the reverse stock split to regain and sustain compliance with Nasdaq requirements. The Board stated that if the reverse stock split is not approved by stockholders, the company’s common stock may be delisted from Nasdaq and could complicate stockholder’s ability to trade the company’s common stock, impact its stock price and affect stockholder’s ability to buy or sell when desired. The Board emphasized the importance of this stockholders’ vote, a positive vote for the reverse stock split as well as the decrease in authorized shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
- Allarity Therapeutics Shares 2024 Milestones and Vision
- Allarity provides 2024 corporate update
- Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
- Allarity Therapeutics Secures Critical Nasdaq Hearing Opportunity